Skip to main content

Lobbying activity

Who's lobbying Congress, for whom, and on what, from federal Lobbying Disclosure Act filings. Covers both chambers, synced daily. 25 filings

Top spenders & firms Spend by issue Political contributions Revolving door

  Showing filings that named HR 1518. Clear
Clear
Q2
AMERICAN SOCIETY OF NEPHROLOGY for AMERICAN SOCIETY OF NEPHROLOGY
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate
Health Issues, Science/Technology
View → Q2
VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate
Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations
View → Q2
OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
2nd Quarter (Apr 1 - June 30) 2026 · Maryland · House · Senate
Budget/Appropriations, Veterans, Medicare/Medicaid, Health Issues
View → Q2
NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION
2nd Quarter (Apr 1 - June 30) 2026 · New York · House · Senate
Budget/Appropriations, Health Issues, Medicare/Medicaid
View → Q1
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $80,000.00 income
Pharmacy, Health Issues, Medicare/Medicaid, Medical/Disease Research/Clinical Labs
View → Q1
AMERICAN KIDNEY FUND for AMERICAN KIDNEY FUND
1st Quarter (Jan 1 - Mar 31) 2026 · Maryland · House · Senate
Health Issues
View → Q1
TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate
Copyright/Patent/Trademark, Health Issues, Pharmacy, Medical/Disease Research/Clinical Labs
View → Q1
TIBER CREEK GROUP for VERTEX PHARMACEUTICALS
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income
Health Issues, Defense
View → Q1
VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate
Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations
View → Q1
OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Maryland · House · Senate
Medicare/Medicaid, Health Issues, Budget/Appropriations, Veterans
View → Q1
NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION
1st Quarter (Jan 1 - Mar 31) 2026 · New York · House · Senate
Budget/Appropriations, Health Issues, Medicare/Medicaid
View → 1A
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Pharmacy, Medical/Disease Research/Clinical Labs
View → Q4
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $80,000.00 income
Taxation/Internal Revenue Code, Medicare/Medicaid, Pharmacy, Health Issues
View → Q4
NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION
4th Quarter (Oct 1 - Dec 31) 2025 · New York · House · Senate
Budget/Appropriations, Health Issues, Medicare/Medicaid
View → Q4
TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate
Health Issues, Pharmacy, Medical/Disease Research/Clinical Labs, Medicare/Medicaid
View → Q4
AMERICAN KIDNEY FUND for AMERICAN KIDNEY FUND
4th Quarter (Oct 1 - Dec 31) 2025 · Maryland · House · Senate
Health Issues
View → Q3
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $70,000.00 income
Health Issues, Medicare/Medicaid, Pharmacy, Medical/Disease Research/Clinical Labs
View → Q3
AMERICAN KIDNEY FUND for AMERICAN KIDNEY FUND
3rd Quarter (July 1 - Sep 30) 2025 · Maryland · House · Senate
Health Issues
View → Q3
NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION
3rd Quarter (July 1 - Sep 30) 2025 · New York · House · Senate
Health Issues, Medicare/Medicaid, Budget/Appropriations
View → Q3
TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate
Health Issues, Pharmacy, Medical/Disease Research/Clinical Labs, Medicare/Medicaid
View → Q2
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Pharmacy, Medical/Disease Research/Clinical Labs
View → Q2
TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate
Health Issues, Pharmacy, Medical/Disease Research/Clinical Labs, Medicare/Medicaid
View → Q1
ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Pharmacy, Medical/Disease Research/Clinical Labs
View → Q1
2359 STRATEGIES for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $12,000.00 income
Medicare/Medicaid, Health Issues, Medical/Disease Research/Clinical Labs, Pharmacy
View → Q1
TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate
Health Issues, Pharmacy, Medical/Disease Research/Clinical Labs, Medicare/Medicaid
View →

Source: federal Lobbying Disclosure Act filings. A filing's bill references are parsed from its activity descriptions, so a bill page shows the filings that named it.

Report a problem